

APPENDIX  
U.S. Serial No. *To Be Assigned* (Docket 2836-E)  
Pending Claims

12. (amended) A method of preparing a dendritic cell population comprising the steps of:
- (a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;
  - (b) transfecting the dendritic cells with a gene encoding antigen; and
  - (c) allowing the dendritic cells to process and express the antigen.
13. (amended) A method according to claim 12, further comprising contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- $\alpha$ , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.
15. (new) A method of preparing a dendritic cell population comprising the steps of:
- (a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;
  - (b) exposing the dendritic cells to an antigen; and
  - (c) allowing the dendritic cells to process and express the antigen.
16. (new) The method according to claim 15 further comprising contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- $\alpha$ , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.
17. (new) The method according to claim 12 wherein the flt3-ligand is a recombinant human flt3-ligand.
18. (new) The method according to claim 13 wherein the flt3-ligand is a recombinant human flt3-ligand.

19. (new) The method according to claim 13 wherein the molecule is a recombinant human GM-CSF.
20. (new) The method according to claim 13 wherein the molecule is CD40 ligand.
21. (new) The method according to claim 13 wherein the molecule is c-kit ligand.
22. (new) The method according to claim 13 wherein the molecule is TNF- $\alpha$ .
23. (new) The method according to claim 15 wherein the flt3-ligand is a recombinant human flt3-ligand.
24. (new) The method according to claim 16 wherein the flt3-ligand is a recombinant human flt3-ligand.
25. (new) The method according to claim 16 wherein the molecule is a recombinant human GM-CSF.
26. (new) The method according to claim 16 wherein the molecule is CD40 ligand.
27. (new) The method according to claim 16 wherein the molecule is c-kit ligand.
28. (new) The method according to claim 16 wherein the molecule is TNF- $\alpha$ .
29. (new) A method of preparing a dendritic cell population, the method comprising contacting *in vitro* hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population, thereby generating the dendritic cell population.
30. (new) The method of claim 29, wherein the hematopoietic stem or progenitor cells have been enriched for the CD34+ phenotype.

31. (new) The method of claim 29, further comprising contacting the dendritic cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- $\alpha$ , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.

32. (new) The method of claim 31, wherein the molecule is GM-CSF.

33. (new) The method of claim 31, wherein the molecule is TNF- $\alpha$ .

34. (new) The method of claim 31, wherein the molecule is c-kit ligand.

35. (new) The method of claim 31, wherein the molecule is CD40 ligand.

36. (new) The method according to claim 29 wherein the flt3-ligand is a recombinant human flt3-ligand.